For example, synovial macrophages from patients with ACPA-negative RA exhibit reprogramming of multiple amino acid metabolic pathways, and this metabolic phenotype is closely linked to disease progression (86)
MEDVi's providers can adjust dosing to manage severity
Integration of GLP-1RA or SGLT2i in Patients With T2D With or at Risk of atherosclerotic CVD PICO 4: In patients with T2D and either atherosclerotic CVD (ASCVD) or high CV risk, what is the role of novel anti-hyperglycemic agents compared with placebo for reduction of a composite of CV death, nonfatal MI, or nonfatal stroke
FDA approves Novo Nordisks oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults owenhaskins Oct 20, 2025 3 min read Novo Nordisk has received FDA approval for Rybelsus for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention)
For advanced HCC patients receiving tyrosine kinase inhibitor therapy, transjugular intrahepatic portosystemic shunt combined with -AR antagonists could reduce the rebleeding rate (5.8% vs
